FDA tentatively approves Lupin’s generic Locoid lotion
The Food and Drug Administration has granted tentative approval to Lupin’s generic Locoid Lotion (hydrocortisone butyrate, 0.1%).
Lupin’s generic Locoid Lotion is indicated for the topical treatment of mild to moderate atopic dermatitis. The product had U.S. sales of roughly $16.1 million for the 12 months ended October 2017, according to IQVIA data.
Lupin’s generic Locoid Lotion is indicated for the topical treatment of mild to moderate atopic dermatitis. The product had U.S. sales of roughly $16.1 million for the 12 months ended October 2017, according to IQVIA data.